Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacare Premium Claims Pole Position On Pazopanib

Malta-Based Generics Developer Reports Two Successful Bioequivalence Trials

Executive Summary

Malta-based generics developer and manufacturer Pharmacare Premium believes it is leading the way on developing a generic pazopanib rival to Novartis’ Votrient cancer treatment for the European market.

You may also be interested in...



Hyloris Pushes Into South America With Maxigesic IV

Hyloris is on a roll with licensing deals for its Maxigesic IV non-opioid pain treatment, with an extension of its existing agreement with Pharma Bavaria to cover South American territories coming hot on the heels of recent developments in the US and Europe.

Australia Extends Biosimilar Education Efforts

Australia’s government has agreed to extend a successful biosimilar education initiative led by the local GBMA industry association.

Lannett Bets On Respiratory And Insulins Pipeline As Sales Falter

Despite turnover dropping by over a fifth in its financial third quarter, Lannett says it is optimistic that respiratory generics and insulins will offer the firm “durable” opportunities in future. The company has also just reorganized its finances to extend its debt maturity by four years, pushing it back past some of its key launches.

Topics

UsernamePublicRestriction

Register

GB150888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel